Guggenheim Reiterates Buy on Stoke Therapeutics, Maintains $60 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.2%

Neg 0% Neu 88.2% Pos 0%

Guggenheim analyst Yatin Suneja reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $60 price target.

Comments

No comments yet. Be the first!